Literature DB >> 10360779

Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy.

C T Yiannoutsos1, E O Major, B Curfman, P N Jensen, M Gravell, J Hou, D B Clifford, C D Hall.   

Abstract

The detection and semiquantitation of JC virus (JCV) DNA in cerebrospinal fluid (CSF) is prognostic of survival and is a marker of the course of progressive multifocal leukoencephalopathy (PML). CSF samples from 15 acquired immunodeficiency syndrome (AIDS) patients with biopsy-proven PML were analyzed by semiquantitative polymerase chain reaction (PCR). A low JCV burden was predictive of longer survival compared with a high JCV burden (median survival from entry, 24 [2-63] vs 7.6 [4-17] weeks). Further analyses indicated a possible threshold of 50 to 100 copies/microl separating high- and moderate-risk cases. Patients with a JCV load below this level survived longer than those with a JCV load above it.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360779     DOI: 10.1002/1531-8249(199906)45:6<816::aid-ana21>3.0.co;2-w

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study.

Authors:  A De Luca; M L Giancola; A Ammassari; S Grisetti; A Cingolani; D Larussa; L Alba; R Murri; G Ippolito; R Cauda; A Monforte; A Antinori
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 2.  Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

Authors:  C T Yiannoutsos; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 3.  Challenges for clinical trials on progressive multifocal leukoencephalopathy.

Authors:  D B Clifford
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

4.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 5.  The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature.

Authors:  Paola Cinque; Simona Bossolasco; Anna Maria Brambilla; Antonio Boschini; Cristina Mussini; Chiara Pierotti; Adriana Campi; Salvatore Casari; Davide Bertelli; Maurizio Mena; Adriano Lazzarin
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

6.  Progressive Multifocal Leukoencephalopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

Review 7.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

8.  A 41-year-old female with progressive multifocal leukoencephalopathy after liver transplant.

Authors:  Zahra Ahmadinejad; Fatemeh Talebi; Niloofar Ayoobi Yazdi; Fereshteh Ghiasvand
Journal:  J Neurovirol       Date:  2019-05-28       Impact factor: 2.643

Review 9.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 10.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.